MYC and neuroblastoma: As about half of “prominent nucleolar formation (+)” or “MYC family protein-driven High-MKI” tumors fail the current super intensive therapy, inhibition of ribosomal RNA gene transcription and aminoacyl-tRNA synthetases by small molecule inhibitors [26, 27] could be a potential therapeutic approach for this subset of unfavorable neuroblastomas as our results suggest (Figure 4).